Correction for Castellanos et al., Stroke 38 (6) 1855-1859.

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

(Stroke. 2007;38:e76.)
© 2007 American Heart Association, Inc.

Correction

In the article entitled "Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study" by Castellanos et al,¹ the authors inadvertently omitted a conflicts-of-interest disclosure statement. The authors regret this error. The Disclosures section of the article should state the following:

"Dr Joaquín Serena, Dr Antoni Dávalos, Dr Mar Castellanos, and Dr José Castillo are joint patent holders of US Patent No. 20070005261 with the title ‘Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof.’ The other authors have nothing to disclose."

The corrected version of this article can now be viewed online at http://stroke.ahajournals.org.

¹[Correction for Vol 38, Number 6, June 2007. Pages 1855–1859.]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content